Blueprint Medicines Corp Debt-to-equity in % from Q2 2019 to Q1 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Blueprint Medicines Corp quarterly Debt-to-equity history and growth rate from Q2 2019 to Q1 2025.
  • Blueprint Medicines Corp Debt-to-equity for the quarter ending March 31, 2025 was 275 %, a 21.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Blueprint Medicines Corp Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 275 -75.2 -21.5% Mar 31, 2025
Q4 2024 272 -51.4 -15.9% Dec 31, 2024
Q3 2024 318 +86.4 +37.3% Sep 30, 2024
Q2 2024 356 +183 +106% Jun 30, 2024
Q1 2024 350 +225 +179% Mar 31, 2024
Q4 2023 323 +239 +282% Dec 31, 2023
Q3 2023 231 +176 +315% Sep 30, 2023
Q2 2023 173 +141 +447% Jun 30, 2023
Q1 2023 125 +102 +448% Mar 31, 2023
Q4 2022 84.8 +65 +329% Dec 31, 2022
Q3 2022 55.7 +38.4 +222% Sep 30, 2022
Q2 2022 31.7 +14.4 +83.6% Jun 30, 2022
Q1 2022 22.9 +3.02 +15.2% Mar 31, 2022
Q4 2021 19.8 -3.76 -16% Dec 31, 2021
Q3 2021 17.3 -13.8 -44.3% Sep 30, 2021
Q2 2021 17.3 -24.3 -58.4% Jun 30, 2021
Q1 2021 19.9 -20.5 -50.7% Mar 31, 2021
Q4 2020 23.5 -22.4 -48.7% Dec 31, 2020
Q3 2020 31.1 -9.35 -23.1% Sep 30, 2020
Q2 2020 41.5 +6.13 +17.3% Jun 30, 2020
Q1 2020 40.3 Mar 31, 2020
Q4 2019 45.9 Dec 31, 2019
Q3 2019 40.5 Sep 30, 2019
Q2 2019 35.4 Jun 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.